Patents by Inventor Karin Von Wachenfeldt
Karin Von Wachenfeldt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11883405Abstract: The present invention relates to a pharmaceutical product comprising a combination of methotrexate and novobiocin, or any pharmaceutically acceptable salts of said compounds, and a pharmaceutical composition comprising (i) a therapeutic amount of methotrexate or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent, (ii) a non-therapeutic amount of novobiocin or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent. The invention further relates to a use of the pharmaceutical product and composition in therapy, such as prevention, progression prophylaxis and/or treatment of autoimmune diseases.Type: GrantFiled: May 31, 2018Date of Patent: January 30, 2024Assignee: AMPLIO PHARMA ABInventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
-
Publication number: 20230108007Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell.Type: ApplicationFiled: June 9, 2022Publication date: April 6, 2023Applicant: Cantargia ABInventors: David Liberg, Camilla Rydberg Millrud, Gabriel Svensson Birkedal, Sara Rattik, Kjell Sjöström, Karin von Wachenfeldt, Caitríona Grönberg
-
Patent number: 11479610Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell.Type: GrantFiled: December 22, 2021Date of Patent: October 25, 2022Assignee: Cantargia ABInventors: David Liberg, Camilla Rydberg Millrud, Gabriel Svensson Birkedal, Sara Rattik, Kjell Sjöström, Karin von Wachenfeldt, Caitríona Grönberg
-
Publication number: 20220267454Abstract: The present invention relates to antibody compositions directed to Interleukin 1 Receptor Accessory Protein (IL1RAP) and their use in the treatment and diagnosis of diseases associated with IL1RAP, such as inflammatory, autoimmune, autoinflammatory and neoplastic disorders.Type: ApplicationFiled: August 15, 2019Publication date: August 25, 2022Applicant: Cantargia ABInventors: Göran Forsberg, David Liberg, Kjell Sjöström, Karin von Wachenfeldt
-
Publication number: 20220242950Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell.Type: ApplicationFiled: December 22, 2021Publication date: August 4, 2022Applicant: Cantargia ABInventors: David Liberg, Camilla Rydberg Millrud, Gabriel Svensson Birkedal, Sara Rattik, Kjell Sjöström, Karin von Wachenfeldt, Caitríona Grönberg
-
Publication number: 20220106396Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human ILIRAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.Type: ApplicationFiled: December 15, 2021Publication date: April 7, 2022Applicant: Cantargia ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin Von Wachenfeldt
-
Patent number: 11236172Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.Type: GrantFiled: July 16, 2020Date of Patent: February 1, 2022Assignee: CANTARGIA ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin Von Wachenfeldt
-
Publication number: 20200339696Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.Type: ApplicationFiled: July 16, 2020Publication date: October 29, 2020Applicant: Cantargia ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin Von Wachenfeldt
-
Patent number: 10752692Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.Type: GrantFiled: March 19, 2019Date of Patent: August 25, 2020Assignee: Cantargia ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt
-
Patent number: 10703723Abstract: The present invention relates to new compounds of formula I and pharmaceutically acceptable salts and/or co-crystals thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as medicaments for the prevention, prophylaxis of progression, and/or treatment of a disease in which modulation of extracellular (chemotactic) cytokines and/or TNF-alpha and or nuclear factor kappa B (NFKB) and/or inflammatory cells is beneficial, such as autoimmune diseases, like rheumatoid arthritis, oligoarthritis, spondyloarthropathy, psoriatic arthritis, psoriasis and inflammatory bowel diseases, such as Crohns' disease and ulcerative colitis.Type: GrantFiled: March 8, 2018Date of Patent: July 7, 2020Assignee: TRULY TRANSLATIONAL SWEDEN ABInventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
-
Publication number: 20200101074Abstract: The present invention relates to a pharmaceutical product comprising a combination of methotrexate and novobiocin, or any pharmaceutically acceptable salts of said compounds, and a pharmaceutical composition comprising (i) a therapeutic amount of methotrexate or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent, (ii) a non-therapeutic amount of novobiocin or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent. The invention further relates to a use of the pharmaceutical product and composition in therapy, such as prevention, progression prophylaxis and/or treatment of autoimmune diseases.Type: ApplicationFiled: May 31, 2018Publication date: April 2, 2020Applicant: Truly Translational Sweden ABInventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
-
Patent number: 10562971Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such as leukemias and melanoma.Type: GrantFiled: August 22, 2018Date of Patent: February 18, 2020Assignee: Cantargia ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt
-
Publication number: 20200017446Abstract: The present invention relates to new compounds of formula I and pharmaceutically acceptable salts and/or co-crystals thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as medicaments for the prevention, prophylaxis of progression, and/or treatment of a disease in which modulation of extracellular (chemotactic) cytokines and/or TNF-alpha and or nuclear factor kappa B (NFKB) and/or inflammatory cells is beneficial, such as autoimmune diseases, like rheumatoid arthritis, oligoarthritis, spondyloarthropathy, psoriatic arthritis, psoriasis and inflammatory bowel diseases, such as Crohns' disease and ulcerative colitis.Type: ApplicationFiled: March 8, 2018Publication date: January 16, 2020Applicant: Truly Translational Sweden ABInventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
-
Publication number: 20190202924Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.Type: ApplicationFiled: March 19, 2019Publication date: July 4, 2019Applicant: CANTARGIA ABInventors: Helena GERSTAMÅ, Thoas FIORETOS, Marcus JÄRÁS, Cecilia Ann-Christin MALMBORG HAGER, Kjell SJÖSTRÖM, Agneta SVEDBERG, Karin VON WACHENFELDT
-
Patent number: 10287357Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.Type: GrantFiled: September 18, 2017Date of Patent: May 14, 2019Assignee: Cantargia ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt
-
Publication number: 20180355049Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such as leukemias and melanoma.Type: ApplicationFiled: August 22, 2018Publication date: December 13, 2018Applicant: CANTARGIA ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt
-
Publication number: 20180327502Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: July 17, 2018Publication date: November 15, 2018Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Emma Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Patent number: 10100119Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such as leukemias and melanoma.Type: GrantFiled: August 6, 2015Date of Patent: October 16, 2018Assignee: Cantargia ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt
-
Publication number: 20180057596Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g., in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: January 24, 2017Publication date: March 1, 2018Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Emma Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20180044425Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such as leukemias and melanoma.Type: ApplicationFiled: August 6, 2015Publication date: February 15, 2018Applicant: CANTARGIA ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt